Pharmamotion has now a new page containing updates on  clopidogrel PPI interactions.

The FDA issued today an early communication about an ongoing safety review of the antiplatelet agent clopidogrel bisulfate (Plavix). The backgroung to this is the recent evidence of:

Here are the recommendations from the FDA until there is further information:

Source: Center for Drug Evaluation and Research. Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix)